171 results
Page 5 of 9
8-K
EX-99.1
3xxqlqs2 wvv3lnsz
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
24ge oiefvzhjwqaf
28 Apr 20
Other Events
8:26am
8-K
EX-99.1
a0uqhca1
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
8-K
EX-99.1
aqdc76jgmt760o0l
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-99.1
yk8q kuvlw5
7 Feb 20
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
4:20pm
424B5
q2krzkvzpjih3qxwg
22 Jan 20
Prospectus supplement for primary offering
5:31pm
8-K
EX-1.1
uazh3yiz whn1cm22k
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-99.1
0gsvf16v ltcvnjakb1
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-99.2
lyghm6nmcu gdahpm8z5
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
424B5
4qwh14k2t90f2 r3
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
vot5e8q8sed
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
9ube mnp12wut
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
ubo8wosik48
13 Jan 20
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
7:09am
8-K
EX-99.1
61881m athrz
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am